Dr. Edward Messing tested this premise—that early treatment is superior to delayed treatment—in a study that was reported in The New England Journal of Medicine back in 1999. One hundred men with cancer found in the lymph nodes after surgery were randomly allocated to start hormone therapy with Lupron immediately after surgery or to wait until the cancer progressed. The 10-year prostate cancer survival rate was 88% in the men who started Lupron right away compared to only 58% in the men who had delayed treatment with Lupron (the average delay was 2 years). READ THE FULL ARTICLE HERE > https://www.verywell.com/starting-treatment-early-for-metastatic-prostate-cancer-part-i-3898559